Education
About Us
Working with TipRanks
Follow Us
Xeris Pharmaceuticals (XERS)
NASDAQ:XERS
XERS Stock Chart & Stats
$7.01
<$0.01(0.15%)
At close: 4:00 PM EST
$7.01
<$0.01(0.15%)
Day’s Range― - ―
52-Week Range$3.48 - $10.08
Previous CloseN/A
Volume530.95K
Average Volume (3M)1.91M
Market Cap
$1.15B
Enterprise Value$1.09B
Total Cash (Recent Filing)$91.60M
Total Debt (Recent Filing)$38.19M
Price to Earnings (P/E)―
Beta1.29
Next Earnings
Mar 11, 2026EPS Estimate
0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.00
Shares Outstanding165,924,290
10 Day Avg. Volume1,357,021
30 Day Avg. Volume1,910,925
Financial Highlights & Ratios
PEG Ratio0.51
Price to Book (P/B)-16.80
Price to Sales (P/S)2.45
P/FCF Ratio-13.15
Enterprise Value/Market Cap0.95
Enterprise Value/Revenue4.11
Enterprise Value/Gross Profit4.92
Enterprise Value/Ebitda41.06
Forecast
1Y Price Target
$9.67Price Target Upside37.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.18
Revenue Forecast (FY)$368.00M
Bulls Say, Bears Say
Bulls Say
Commercial MomentumAnalyst highlights commercial momentum across the product portfolio, with strong Recorlev uptake and an expanding patient base that could drive sustained top-line growth.
Guidance Credibility And Re-ratingAnalyst states that continued commercial outperformance and a strong quarterly pre-announcement could increase credibility of long-range revenue targets and prompt the stock to be valued more on forward forecasts, implying meaningful upside.
Profitability And MarginsAnalyst notes expansion of gross margin to 85% and attainment of GAAP profitability as evidence of improving operating leverage that could translate into higher earnings per share as sales grow.
Bears Say
Regulatory And Execution RisksAnalyst cites regulatory setbacks for a related product and highlights clinical, regulatory, commercial execution, and intellectual property risks that could negatively affect long-term revenue forecasts.
Sustainability Of GrowthAnalyst questions whether the main drug's growth drivers can be sustained, noting reliance on prescription momentum that, if weakened, could slow revenue expansion.
Visibility And VolatilityAnalyst warns that limited visibility into prescription trends between reporting periods increases share volatility and makes interim company updates unusually influential on the stock price.
Xeris Pharmaceuticals News
XERS FAQ
What was Xeris Pharmaceuticals’s price range in the past 12 months?
Xeris Pharmaceuticals lowest stock price was $3.48 and its highest was $10.08 in the past 12 months.
What is Xeris Pharmaceuticals’s market cap?
Xeris Pharmaceuticals’s market cap is $1.15B.
When is Xeris Pharmaceuticals’s upcoming earnings report date?
Xeris Pharmaceuticals’s upcoming earnings report date is Mar 11, 2026 which is in 25 days.
How were Xeris Pharmaceuticals’s earnings last quarter?
Xeris Pharmaceuticals released its earnings results on Nov 06, 2025. The company reported $0 earnings per share for the quarter, missing the consensus estimate of $0.006 by -$0.006.
Is Xeris Pharmaceuticals overvalued?
According to Wall Street analysts Xeris Pharmaceuticals’s price is currently Undervalued.
Does Xeris Pharmaceuticals pay dividends?
Xeris Pharmaceuticals does not currently pay dividends.
What is Xeris Pharmaceuticals’s EPS estimate?
Xeris Pharmaceuticals’s EPS estimate is 0.02.
How many shares outstanding does Xeris Pharmaceuticals have?
Xeris Pharmaceuticals has 165,924,290 shares outstanding.
What happened to Xeris Pharmaceuticals’s price movement after its last earnings report?
Xeris Pharmaceuticals reported an EPS of $0 in its last earnings report, missing expectations of $0.006. Following the earnings report the stock price went down -21.884%.
Which hedge fund is a major shareholder of Xeris Pharmaceuticals?
Currently, no hedge funds are holding shares in XERS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Xeris Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.67 (37.95% Upside)
$9.67 (37.95% Upside)
Blogger Sentiment
Bullish
XERS Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 501.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $976.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 5.2%
Last 30 Days ▼ 9.0%
Last 30 Days ▼ 9.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
96.05%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
15.29%
Trailing 12-Months
Company Description
Xeris Pharmaceuticals
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
XERS Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted Xeris Biopharma's strong financial performance with record revenue growth and successful product performance, particularly for RECORLEV. However, there are increased expenses and potential competitive challenges on the horizon. Despite these concerns, the company's positive financial milestones and strategic growth plans suggest an optimistic outlook.View all XERS earnings summariesXERS Stock 12 Month Forecast
Average Price Target
$9.67
▲(37.95% Upside)
Technical Analysis
Syndax Pharmaceuticals
―
Zymeworks
―
Arcus Biosciences
―
Stoke Therapeutics
―
Rapport Therapeutics, Inc.
―
Ownership Overview
5.55% Insiders
10.90% Mutual Funds
0.18% Other Institutional Investors
70.97% Public Companies and
Individual Investors